Published in J Neurosci on February 01, 2001
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors. PLoS Biol (2015) 2.30
Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J (2006) 2.01
mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol (2006) 1.93
Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia (2010) 1.70
Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev (2011) 1.66
Cannabinoids and neuroinflammation. Br J Pharmacol (2004) 1.62
Altered white matter microstructure in adolescent substance users. Psychiatry Res (2009) 1.58
Astrocytes in Alzheimer's disease. Neurotherapeutics (2010) 1.47
Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv (2011) 1.38
Endocannabinoid signaling in microglial cells. Neuropharmacology (2008) 1.36
Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling. Proc Natl Acad Sci U S A (2006) 1.35
Candidate genes for cannabis use disorders: findings, challenges and directions. Addiction (2009) 1.31
Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens. J Comp Neurol (2006) 1.22
The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology (Berl) (2003) 1.16
Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience (2013) 1.14
The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol (2010) 1.11
Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex. Brain Res (2006) 1.10
Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther (2011) 1.08
Adenosine-cannabinoid receptor interactions. Implications for striatal function. Br J Pharmacol (2010) 1.07
Characterization of cannabinoid-1 receptors in the locus coeruleus: relationship with mu-opioid receptors. Brain Res (2009) 1.07
Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacol Res (2007) 1.07
Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology (2008) 1.06
Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci (2009) 1.05
Analysis of the effects of cannabinoids on identified synaptic connections in the caudate-putamen by paired recordings in transgenic mice. J Physiol (2006) 1.04
Electroacupuncture modulates vlPAG release of GABA through presynaptic cannabinoid CB1 receptors. J Appl Physiol (1985) (2009) 1.03
A review of the interactions between alcohol and the endocannabinoid system: implications for alcohol dependence and future directions for research. Alcohol (2012) 1.02
Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol (2009) 1.02
Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizophr Res (2011) 1.01
Signal transduction via cannabinoid receptors. CNS Neurol Disord Drug Targets (2009) 0.99
Proenkephalin mediates the enduring effects of adolescent cannabis exposure associated with adult opiate vulnerability. Biol Psychiatry (2012) 0.97
Opioid receptor heteromers in analgesia. Expert Rev Mol Med (2012) 0.94
Dynamic imaging of cannabinoid receptor 1 vesicular trafficking in cultured astrocytes. ASN Neuro (2009) 0.94
Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology (Berl) (2005) 0.93
An Introduction to the Endogenous Cannabinoid System. Biol Psychiatry (2015) 0.93
Mu-opioid and corticotropin-releasing-factor receptors show largely postsynaptic co-expression, and separate presynaptic distributions, in the mouse central amygdala and bed nucleus of the stria terminalis. Neuroscience (2009) 0.92
Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine. Mol Pain (2009) 0.90
Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex. Neurosci Lett (2007) 0.89
Withdrawal from THC during adolescence: sex differences in locomotor activity and anxiety. Behav Brain Res (2012) 0.89
AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies. Neuropharmacology (2012) 0.89
Modulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction. Front Psychiatry (2013) 0.88
Differential gene expression in migratory streams of cortical interneurons. Eur J Neurosci (2011) 0.88
Regulated exocytosis in astrocytic signal integration. Neurochem Int (2010) 0.87
Changes in cannabinoid receptors, aquaporin 4 and vimentin expression after traumatic brain injury in adolescent male mice. Association with edema and neurological deficit. PLoS One (2015) 0.86
CB1 Cannabinoid Receptor Expression in the Striatum: Association with Corticostriatal Circuits and Developmental Regulation. Front Pharmacol (2012) 0.86
Cannabinoid modulation of the dopaminergic circuitry: implications for limbic and striatal output. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.86
Decreased parvalbumin immunoreactivity in the cortex and striatum of mice lacking the CB1 receptor. Synapse (2011) 0.85
Endocannabinoid-dopamine interactions in striatal synaptic plasticity. Front Pharmacol (2012) 0.85
Pharmacological characterization of inhibitory effects of postsynaptic opioid and cannabinoid receptors on calcium currents in neonatal rat nucleus tractus solitarius. Br J Pharmacol (2006) 0.84
Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance. J Med Chem (2013) 0.84
Optogenetic identification of an intrinsic cholinergically driven inhibitory oscillator sensitive to cannabinoids and opioids in hippocampal CA1. J Physiol (2013) 0.83
CB1 receptors modulate the intake of a sweetened-fat diet in response to μ-opioid receptor stimulation of the nucleus accumbens. Pharmacol Biochem Behav (2010) 0.83
Functional diversity on synaptic plasticity mediated by endocannabinoids. Philos Trans R Soc Lond B Biol Sci (2012) 0.82
Opposite function of dopamine D1 and N-methyl-D-aspartate receptors in striatal cannabinoid-mediated signaling. Eur J Neurosci (2011) 0.82
The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia. Front Pharmacol (2014) 0.82
Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. Brain Struct Funct (2014) 0.81
Astrocytes in endocannabinoid signalling. Philos Trans R Soc Lond B Biol Sci (2014) 0.81
HINT1 protein cooperates with cannabinoid 1 receptor to negatively regulate glutamate NMDA receptor activity. Mol Brain (2013) 0.80
Involvement of opioid system in cognitive deficits induced by ∆⁹-tetrahydrocannabinol in rats. Psychopharmacology (Berl) (2011) 0.80
Cannabinoid receptors couple to NMDA receptors to reduce the production of NO and the mobilization of zinc induced by glutamate. Antioxid Redox Signal (2013) 0.80
Differential effect of opioid and cannabinoid receptor blockade on heroin-seeking reinstatement and cannabinoid substitution in heroin-abstinent rats. Br J Pharmacol (2011) 0.80
In vivo opioid receptor heteromerization: where do we stand? Br J Pharmacol (2014) 0.80
Presynaptic Spike Timing-Dependent Long-Term Depression in the Mouse Hippocampus. Cereb Cortex (2016) 0.80
Morphine-induced trafficking of a mu-opioid receptor interacting protein in rat locus coeruleus neurons. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.80
Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection. Mol Neurodegener (2015) 0.79
Modulation of NMDA and AMPA-mediated synaptic transmission by CB1 receptors in frontal cortical pyramidal cells. Brain Res (2010) 0.79
New insights on endocannabinoid transmission in psychomotor disorders. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.79
Endocannabinoids mediate synaptic plasticity at glutamatergic synapses on spiny neurons within a basal ganglia nucleus necessary for song learning. J Neurophysiol (2010) 0.79
Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med (2015) 0.79
Endocannabinoids and Heterogeneity of Glial Cells in Brain Function. Front Integr Neurosci (2016) 0.78
Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage. Neurotherapeutics (2015) 0.78
Endocannabinoid modulation of hyperaemia evoked by physiologically relevant stimuli in the rat primary somatosensory cortex. Br J Pharmacol (2010) 0.77
Receptor and channel heteromers as pain targets. Pharmaceuticals (Basel) (2012) 0.77
MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse. Psychol Med (2012) 0.77
The cannabinoid receptor agonists, anandamide and WIN 55,212-2, do not directly affect mu opioid receptors expressed in Xenopus oocytes. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.77
Pharmacological Profiles of Oligomerized μ-Opioid Receptors. Cells (2013) 0.77
Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe? Neurotherapeutics (2015) 0.77
High Times for Painful Blues: The Endocannabinoid System in Pain-Depression Comorbidity. Int J Neuropsychopharmacol (2015) 0.77
Constitutive activity at the cannabinoid CB(1) receptor and behavioral responses. Methods Enzymol (2010) 0.76
Enhanced dendritic availability of μ-opioid receptors in inhibitory neurons of the extended amygdala in mice deficient in the corticotropin-releasing factor-1 receptor. Synapse (2011) 0.76
Opioid modulation of GABA release in the rat inferior colliculus. BMC Neurosci (2004) 0.76
[The endogenous opioid system and drug addiction]. Ann Pharm Fr (2010) 0.76
The ON:OFF switch, σ1R-HINT1 protein, controls GPCR-NMDA receptor cross-regulation: implications in neurological disorders. Oncotarget (2015) 0.76
Endocannabinoids and striatal function: implications for addiction-related behaviours. Behav Pharmacol (2015) 0.76
Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction. Oncotarget (2016) 0.75
Filming the glial dreams: real-time imaging of cannabinoid receptor trafficking in astrocytes. ASN Neuro (2009) 0.75
Effect of interaction between acute administration of morphine and cannabinoid compounds on spontaneous excitatory and inhibitory postsynaptic currents of magnocellular neurons of supraoptic nucleus. Iran J Basic Med Sci (2016) 0.75
Spatial distribution of cannabinoid receptor type 1 (CB1) in normal canine central and peripheral nervous system. PLoS One (2017) 0.75
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci (1999) 4.65
Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience (1998) 4.39
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
Modulation of Ca2+ channels by G-protein beta gamma subunits. Nature (1996) 3.79
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol (1995) 2.95
Electrophysiological characterization of GABAergic neurons in the ventral tegmental area. J Neurosci (1998) 2.32
Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. J Comp Neurol (1992) 2.21
Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci (2001) 2.15
Reconstitution of muscarinic modulation of the KCNQ2/KCNQ3 K(+) channels that underlie the neuronal M current. J Neurosci (2000) 2.15
Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci U S A (1993) 2.10
Optimization of differential immunogold-silver and peroxidase labeling with maintenance of ultrastructure in brain sections before plastic embedding. J Neurosci Methods (1990) 2.06
Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol (1997) 2.05
Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology (2001) 2.03
Ultrastructural localization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets. J Neurosci (1994) 1.85
Internalization and recycling of the CB1 cannabinoid receptor. J Neurochem (1999) 1.82
Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization. J Neurosci (1999) 1.80
GABA-containing neurons in the ventral tegmental area project to the nucleus accumbens in rat brain. Brain Res (1995) 1.78
Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience (1999) 1.77
The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci (1996) 1.70
The anatomy of neuropeptide-Y-containing neurons in rat brain. Neuroscience (1985) 1.64
Failed coronary stent deployment. Am Heart J (1998) 1.60
The localization of the brain-specific inorganic phosphate transporter suggests a specific presynaptic role in glutamatergic transmission. J Neurosci (1998) 1.58
Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. J Neurosci (2001) 1.58
Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine. J Neurosci (1996) 1.52
Monoamine-synthesizing enzymes in central dopaminergic, noradrenergic and serotonergic neurons. Immunocytochemical localization by light and electron microscopy. J Histochem Cytochem (1976) 1.40
Towards early defibrillation--a nurse training programme in the use of automated external defibrillators. Resuscitation (1995) 1.38
In the rat medial nucleus accumbens, hippocampal and catecholaminergic terminals converge on spiny neurons and are in apposition to each other. Brain Res (1990) 1.37
Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature (2000) 1.36
CB1 cannabinoid receptors are enriched in the perisynaptic annulus and on preterminal segments of hippocampal GABAergic axons. Neuroscience (2005) 1.35
Ultrastructural localization of substance P in neurons of rat spinal cord. Brain Res (1977) 1.34
Topography of serotonin neurons in the dorsal raphe nucleus that send axon collaterals to the rat prefrontal cortex and nucleus accumbens. Brain Res (1993) 1.34
Cellular sites for dynorphin activation of kappa-opioid receptors in the rat nucleus accumbens shell. J Neurosci (1999) 1.32
CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol (2007) 1.32
GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience (2000) 1.25
Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res (1987) 1.25
Chemical and structural analysis of the relation between cortical inputs and tyrosine hydroxylase-containing terminals in rat neostriatum. Brain Res (1984) 1.20
Plasmalemmal mu-opioid receptor distribution mainly in nondopaminergic neurons in the rat ventral tegmental area. Synapse (2001) 1.20
Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience (2005) 1.18
GABA-labeled terminals form proportionally more synapses with dopaminergic neurons containing low densities of tyrosine hydroxylase-immunoreactivity in rat ventral tegmental area. Brain Res (1991) 1.18
Ultrastructural immunocytochemical localization of tyrosine hydroxylase in the neostriatum. Brain Res (1981) 1.17
Light-microscopic immunocytochemical localization of tyrosine hydroxylase in prenatal rat brain. I. Early ontogeny. J Comp Neurol (1981) 1.16
Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest Ophthalmol Vis Sci (1999) 1.16
The dopamine transporter: comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens. J Neurosci (1997) 1.15
Protein kinase C disrupts cannabinoid actions by phosphorylation of the CB1 cannabinoid receptor. J Neurosci (1998) 1.14
A radioautographic study of the efferent pathways of the nucleus locus coeruleus. J Comp Neurol (1974) 1.13
Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. Synapse (2001) 1.12
Ultrastructural localization of monoamines and peptides in rat area postrema. Fed Proc (1984) 1.12
The mammalian brain high-affinity L-proline transporter is enriched preferentially in synaptic vesicles in a subpopulation of excitatory nerve terminals in rat forebrain. J Neurosci (1999) 1.12
A light and electron microscopic study of the CB1 cannabinoid receptor in primate brain. Neuroscience (1999) 1.12
Dual ultrastructural immunocytochemical labeling of mu and delta opioid receptors in the superficial layers of the rat cervical spinal cord. Brain Res (1997) 1.12
N-methyl-D-aspartate receptors are present in vagal afferents and their dendritic targets in the nucleus tractus solitarius. Neuroscience (1999) 1.11
The vesicular monoamine transporter 2 is present in small synaptic vesicles and preferentially localizes to large dense core vesicles in rat solitary tract nuclei. Proc Natl Acad Sci U S A (1995) 1.11
Preferential localization of a vesicular monoamine transporter to dense core vesicles in PC12 cells. J Cell Biol (1994) 1.10
Cannabinoid signaling in inhibitory autaptic hippocampal neurons. Neuroscience (2009) 1.10
Cellular localization of tyrosine hydroxylase by immunohistochemistry. J Histochem Cytochem (1975) 1.09
Ultrastructure of serotonin-immunoreactive terminals in the core and shell of the rat nucleus accumbens: cellular substrates for interactions with catecholamine afferents. J Comp Neurol (1993) 1.09
CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. Neuroreport (2001) 1.09
Association of sorcin with the cardiac ryanodine receptor. J Biol Chem (1995) 1.09
COX-2 and fatty acid amide hydrolase can regulate the time course of depolarization-induced suppression of excitation. Br J Pharmacol (2011) 1.09
Brain tryptophan hydroxylase: purification of, production of antibodies to, and cellular and ultrastructural localization in serotonergic neurons of rat midbrain. Proc Natl Acad Sci U S A (1975) 1.08
Anatomical substrates for baroreflex sympathoinhibition in the rat. Brain Res Bull (2000) 1.08
Functional expression of cell surface cannabinoid CB(1) receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons. Neuroscience (2000) 1.08
Ultrastructural localization of tyrosine hydroxylase in the rat ventral tegmental area: relationship between immunolabeling density and neuronal associations. J Neurosci (1990) 1.07
Catecholamine biosynthetic enzymes are expressed in replicating cells of the peripheral but not the central nervous system. Proc Natl Acad Sci U S A (1980) 1.06
Cannabinoid CB1 receptors and ligands in vertebrate retina: localization and function of an endogenous signaling system. Proc Natl Acad Sci U S A (1999) 1.06
Cholinergic axon terminals in the ventral tegmental area target a subpopulation of neurons expressing low levels of the dopamine transporter. J Comp Neurol (1999) 1.06
mu-opioid receptors are present in vagal afferents and their dendritic targets in the medial nucleus tractus solitarius. J Comp Neurol (2000) 1.05
Vesicular monoamine transporter-2: immunogold localization in striatal axons and terminals. Synapse (1997) 1.04
Immunogold localization of the dopamine transporter: an ultrastructural study of the rat ventral tegmental area. J Neurosci (1997) 1.04
Compartmentalization of endocannabinoids into lipid rafts in a dorsal root ganglion cell line. Br J Pharmacol (2007) 1.04
G-protein beta-subunit specificity in the fast membrane-delimited inhibition of Ca2+ channels. J Neurosci (1998) 1.04
Ultrastructural immunocytochemical localization of mu-opioid receptors in rat nucleus accumbens: extrasynaptic plasmalemmal distribution and association with Leu5-enkephalin. J Neurosci (1996) 1.04
A mutation in the second transmembrane region of the CB1 receptor selectively disrupts G protein signaling and prevents receptor internalization. Mol Pharmacol (1999) 1.03
Postnatal development of mu-opioid receptors in the rat caudate-putamen nucleus parallels asymmetric synapse formation. Neuroscience (2003) 1.03
Synaptic interaction of vagal afferents and catecholaminergic neurons in the rat nucleus tractus solitarius. Brain Res (1983) 1.03
Preferential cytoplasmic localization of delta-opioid receptors in rat striatal patches: comparison with plasmalemmal mu-opioid receptors. J Neurosci (2001) 1.03
Distribution of dopamine-, noradrenaline-, and adrenaline-containing cell bodies in the rat medulla oblongata: demonstrated by the immunocytochemical localization of catecholamine biosynthetic enzymes. J Comp Neurol (1982) 1.02
Serotonergic neurons in the peripheral nervous system: identification in gut by immunohistochemical localization of tryptophan hydroxylase. Proc Natl Acad Sci U S A (1977) 1.02
Antibodies to the beta-adrenergic receptor: attenuation of catecholamine-sensitive adenylate cyclase and demonstration of postsynaptic receptor localization in brain. Proc Natl Acad Sci U S A (1983) 1.02
Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus. Neuroscience (2010) 1.01
Immunocytochemical localization of enkephalin in the neostriatum of rat brain: a light and electron microscopic study. J Comp Neurol (1980) 1.01
Distribution of angiotensin type 1a receptor-containing cells in the brains of bacterial artificial chromosome transgenic mice. Neuroscience (2012) 1.01
Impact of nutrition on oocyte quality: cumulative effects of body composition and diet leading to hyperinsulinemia in cattle. Biol Reprod (2005) 1.01
Electron microscopic localization of substance P and enkephalin in axon terminals related to dendrites of catecholaminergic neurons. Brain Res (1979) 1.00
Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS. Br J Pharmacol (2014) 1.00
Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area. Brain Res (2000) 1.00
Angiotensin II subtype 1A (AT1A) receptors in the rat sensory vagal complex: subcellular localization and association with endogenous angiotensin. Neuroscience (2003) 1.00
Light-microscopic immunocytochemical localization of tyrosine hydroxylase in prenatal rat brain. II. Late ontogeny. J Comp Neurol (1981) 0.99
Strain-dependent variations in number of midbrain dopaminergic neurones. Nature (1976) 0.97
Localization of the delta-opioid receptor and dopamine transporter in the nucleus accumbens shell: implications for opiate and psychostimulant cross-sensitization. Synapse (1999) 0.97
Input from central nucleus of the amygdala efferents to pericoerulear dendrites, some of which contain tyrosine hydroxylase immunoreactivity. J Neurosci Res (1996) 0.96
Ultrastructural immunocytochemical localization of the dopamine D2 receptor within GABAergic neurons of the rat striatum. Brain Res (1997) 0.96
Postnatal development of cannabinoid receptor type 1 expression in rodent somatosensory cortex. Neuroscience (2007) 0.95
Ultrastructural immunocytochemical localization of the N-methyl-D-aspartate receptor and tyrosine hydroxylase in the shell of the rat nucleus accumbens. Brain Res (1996) 0.95
Ultrastructural basis for interactions between central opioids and catecholamines. I. Rostral ventrolateral medulla. J Neurosci (1989) 0.94
Ultrastructural localization of tyrosine hydroxylase in noradrenergic neurons of brain. Proc Natl Acad Sci U S A (1975) 0.94
Dendritic spines containing mu-opioid receptors in rat striatal patches receive asymmetric synapses from prefrontal corticostriatal afferents. J Comp Neurol (1998) 0.94